Personal profile
Education/Academic qualification
Medical School (MD), University of Milan
1970 → 1976
External positions
Associate Editor European Neuropsychopharmacology
2014 → 2019
Chief Psychiatrist Dep. of Psychiatry B, Sheba Medical Centre
2012 → 2016
Chief Editor European Neuropsychopharmacology
2009 → 2014
Co-Founder Tangent Data CRO
2003 → 2017
Chief Psychiatrist Dep. of Psychiatry, Sheba Medical Centre
2001 → 2012
Associate Director Abarbanel Psychiatric Hospital Tel-Aviv
2000 → 2001
President Medical Center for Alzheimer
2000 → …
Psychiatric Services and Memory Clinic Sheba Medical Center Tel-Aviv
1995 → 1999
Associate Director for R&D, Pilgrim Psychiatric Hospital
1991 → 1995
Unit Head and Division Director, Mount Sinai N.Y
1985 → 1995
Resident in Psychiatry, Mount Sinai School of Medicine
1982 → 1985
Resident in Psychiatry, Valhalla School of Medicine, Metropolitan Hospital NY
1981 → 1982
Resident in Cardiology and Medicine, Tel Aviv Medical Centre
1976 → 1980
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
-
SDG 3 Good Health and Well-being -
SDG 8 Decent Work and Economic Growth -
SDG 10 Reduced Inequalities -
SDG 16 Peace, Justice and Strong Institutions
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
Is it Possible To Identify Patients After Their First Hospitalization for a Psychotic Disorder Who Do Not Use Anti-Psychotics and are Not Later Rehospitalized?
Krivoy, A., Tiihonen, J., Nissan, J., Dotan, A., Arnheim, D., Menkes-Caspi, N., Taub, S., Tuppurainen, H., Mittendorfer-Rutz, E., Davidson, M., Davis, J. M., Weiser, M. & Taipale, H., 1 Jan 2026, In: Schizophrenia Bulletin. 52, 1, sbaf011.Research output: Contribution to journal › Article › peer-review
Open Access -
The effect of switching antipsychotics to aripiprazole versus paliperidone on weight/cardiometabolic parameters: 18-month follow-up findings from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST)
de Boer, N., Vučko, Z., Koster, D. I. J., van der Horst, M., Davidson, M., Cahn, W. & Luykx, J. J., Jan 2026, In: European Neuropsychopharmacology. 102, p. 49-57 9 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Cognitive changes in schizophrenia before and after illness onset: A meta-analysis examining consistency in measurement tools as a moderator
Cohen, N., Weiser, M., Reichenberg, A., Davis, J. M., Davidson, M. & Werbeloff, N., Sept 2025, In: Schizophrenia Research: Cognition. 41, 100371.Research output: Contribution to journal › Review article › peer-review
Open Access -
Impact of Long-Acting Injectable Versus Oral Antipsychotic Treatment on All-Cause Discontinuation Risk in People with Early Phase Schizophrenia and Comorbid Substance Use Disorder: A Secondary Analysis of the EULAST Randomized Trial
EULAST Study Group, 2025, (Accepted/In press) In: CNS Drugs.Research output: Contribution to journal › Article › peer-review
Open Access -
Roluperidone monotherapy, a treatment for negative symptoms in schizophrenia
Davidson, M., Noel, N., Schmitt, F. & Luthringer, R., 1 Jun 2025, In: International Journal of Neuropsychopharmacology. 28, 6, pyaf032.Research output: Contribution to journal › Article › peer-review
Open Access